$2.01 Billion is the total value of Camber Capital Management LP's 28 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALXN | ALEXION PHARMACEUTICALS INC | $81,108,000 | +38.8% | 600,000 | 0.0% | 4.04% | +45.8% | |
NKTR | NEKTAR THERAPEUTICS | $67,200,000 | +2.2% | 2,000,000 | 0.0% | 3.35% | +7.3% | |
MNTA | MOMENTA PHARMACEUTICALS INC | $58,120,000 | +31.6% | 4,000,000 | 0.0% | 2.90% | +38.2% | |
THOR | SYNTHORX INC | $37,931,000 | +17.2% | 1,862,116 | 0.0% | 1.89% | +23.1% | |
ZYME | ZYMEWORKS INC | $35,046,000 | +10.2% | 2,166,000 | 0.0% | 1.75% | +15.8% | |
AMAG | AMAG PHARMACEUTICALS INC | $34,132,000 | -15.2% | 2,650,000 | 0.0% | 1.70% | -10.9% | |
EGRX | EAGLE PHARMACEUTICALS INC | $14,723,000 | +25.3% | 291,600 | 0.0% | 0.73% | +31.8% | |
STRO | SUTRO BIOPHARMA INC | $6,834,000 | +26.3% | 600,000 | 0.0% | 0.34% | +32.7% | |
SGRY | SURGERY PARTNERS INC | $1,806,000 | +15.3% | 160,084 | 0.0% | 0.09% | +21.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
MYLAN NV | 21 | Q3 2020 | 10.1% |
AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
Solid Biosciences Inc. | December 12, 2022 | ? | ? |
AVROBIO, Inc. | February 14, 2022 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
Change Healthcare Inc. | February 16, 2021 | ? | ? |
GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-30 |
13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.